Data Collection for Patients With Low Grade Ovarian Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00488878|
Recruitment Status : Recruiting
First Posted : June 20, 2007
Last Update Posted : August 21, 2017
The goal of this psychosocial research study is to collect information on patients with one of the above-mentioned low-grade tumors. Researchers want to maintain these patients' information in a research database to help learn and better understand these tumor types and to help develop better treatments for them.
This is an investigational study. There will be no cost for participating in this research study. Up to 2000 patients from MD Anderson will take part in this study.
|Condition or disease||Intervention/treatment|
|Ovarian Cancer Peritoneum Tumors||Behavioral: Data Collection|
Low-grade tumors of female organs are considered rare. Because of this, doctors do not know the best treatment for these kinds of tumors. Researchers want to learn more about patients' experience with these types of cancer to help find ways to develop better therapies to treat them.
If you agree to take part in this study, information about your type of cancer, the type of treatment you had or are having, and details about your follow-up care will be entered into a research database. These data will be collected from patients seen at MD Anderson since January, 1950. This information will serve as a basis for research studies about patients with low-grade ovarian tumors.
Your data will mostly come from your MD Anderson medical record. However, information may also be requested from you, your local doctor, or an outside hospital. Information collected from sources other than MD Anderson will be included in your MD Anderson medical record as well as entered into this study's database.
Information may be directly collected from you, if there are additional questions not provided in your medical records, if your information is not complete, or if your information collected from other sources does not match what is in your MD Anderson medical record.
To help ensure confidentiality, the database will be password-protected with access strictly limited to study staff.
This research database will be updated at least once a year to include information about your current treatment and/or follow-up care. This information is usually collected from your MD Anderson medical record, or it may be necessary to contact you directly. This information will be collected indefinitely. If you wish to end your participation in this study, you may request that your data remain in the database or that your information be deleted from the database.
This is an investigational study. Up to 2000 patients from MD Anderson will take part in this study.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Data Collection for Patients With Low Grade Ovarian Carcinoma|
|Actual Study Start Date :||May 2006|
|Estimated Primary Completion Date :||May 2034|
|Estimated Study Completion Date :||May 2034|
|Ovarian Cancer Data Collection||
Behavioral: Data Collection
Data collection from ovarian cancer patients seen at M.D. Anderson since January, 1950.
- Data Collection for Patients with Low Grade Ovarian Carcinoma [ Time Frame: 28 Years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00488878
|Contact: Lisa Nathan||713-745-3837|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator: David Gershenson, MD|
|Principal Investigator:||David Gershenson, MD||M.D. Anderson Cancer Center|